Virtual Library

Start Your Search

T. Lesser



Author of

  • +

    P1.05 - Poster Session with Presenters Present (ID 457)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Early Stage NSCLC
    • Presentations: 1
    • +

      P1.05-022 - Circulating Tumor Cell Isolation to Monitor NSCLC Patients over the Course of Treatment (ID 5975)

      14:30 - 15:45  |  Author(s): T. Lesser

      • Abstract
      • Slides

      Background:
      Compared to the investigation of the primary tumor or a biopsy taken from a distant metastasis, the investigation of a patient’s blood is relatively simple, less invasive and can be performed repeatedly. Thus, CTC (circulating tumor cells) investigation can be used as a real-time marker for staging, disease progression and therapy responsiveness. Cancer mortality might be reduced dramatically when the disease and its metastatic spread are detected and characterized early and can therefore be treated in an optimal fashion. The GILUPI CellCollector[® ]offers medical personnel at any point-of-care with the unique opportunity to enrich these CTCs in vivo. Here, we conducted a study using this effective device, to monitor CTC counts before as well as on different time points after surgery in non-small cell lung cancer (NSCLC) patients and further to characterize the CTCs on a molecular level.

      Methods:
      In total, 20 NSCLC patients (different stages) were screened for CTCs at different time points: preoperative, 30 minutes after tumor resection, 1 week postoperative as well as in 3-monthly intervals up to 2 years. In addition, 1 patient with a benign lung disease were included in this study.

      Results:
      CTCs were isolated independent from tumor stages and even in quite early cases CTCs could be detected. Moreover, a difference between CTC occurrence before and after surgery was seen and a correlation between CTC enumeration and clinical lack of recurrence could be detected.

      Conclusion:
      The GILUPI CellCollector® overcomes blood volume limitations of other diagnostic approaches and thereby increases the diagnostic sensitivity of CTC analysis. Future implementation into clinical practice may improve early detection, prognosis and therapy monitoring of cancer patients. Besides enumeration, captured CTCs are ready for molecular characterization and will help to establish more personalized treatment regiments since knowledge of the molecular make-up of the cancer cells to be defeated is an indispensable prerequisite to use targeted therapies efficiently.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.